<DOC>
	<DOCNO>NCT01257620</DOCNO>
	<brief_summary>This exploratory study design determine effect probiotic Bifidobacterium infantis vs. placebo orally administer period 3 week clinical feature , Quality Life parameter ( QoL ) , intestinal permeability inflammatory marker patient positive serological evidence Celiac Disease .</brief_summary>
	<brief_title>Clinical Trial Effects Bifidobacterium Infantis Active Celiac Disease</brief_title>
	<detailed_description>Objective : This exploratory study design determine effect probiotic Bifidobacterium infantis vs. placebo orally administer period 3 week clinical feature , Quality Life parameter ( QoL ) , intestinal permeability inflammatory marker patient serological evidence CD ( positive serological marker ) . The testing period approximately three week result serological test intestinal biopsy procedure time subject consume gluten-containing diet . Study Design : A 3-weeks duration , placebo-controlled , double-blind , randomize study plan ambulatory ( non-hospitalized outpatient ) patient , 2 parallel group . Treatment arm follow : A ) . Placebo 2 capsule 3 time daily ( morning , even night ) . B ) . Probiotics ( Bifidobacterium infantis ) 2 capsule 3 time per day ( morning , even night ) .</detailed_description>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Signing Informed consent . Men woman , 1875 year old . BMI 18.5 35 . Patients shall positive CDrelated serology ( combine positivity DGP/tTG Screen plus IgA antitTG IgA aDGP test ) . Patients abstain take medication prohibit study 7 day prior enrolment end trial : NSAIDs , aspirin , lactulose , probiotic prebiotics form administration ( eg . Yogurts dairy product ) .. Alcohol consumption prohibit period . Patients commit attend scheduled day , accordance study calendar . To interested participate trial Patients refractory CD severe complication thereof , enteropathyassociated Tcell Lymphoma ( EATL ) , ulcerative jejunitis , perforation , severe osteoporosis , malnutrition , among others . Individuals symptom suggestive lymphoma serious CD complication take special care recentlydiagnosed patient , 50 year old old , EATL must rule standard method . Individuals active chronic GI pathology like Crohn 's disease , ulcerative colitis irritable bowel syndrome , microscopic colitis , lactose intolerance . Patients Type 1 Type 2 diabetes autoimmune disease , autoimmune hepatitis primary biliary cirrhosis . Individuals comorbidities whose participation , investigator 's judgment , would inadvisable ; instance , unstable clinical condition chronic obstructive pulmonary disease , angina pectoris , severe cardiorespiratory condition , etc . Individuals symptomatic neurological psychiatric condition could potentially interfere study . Individuals clinical severity require immediate treatment consideration investigator . Patients hemoglobin level less 8.5 g/dL donate blood last 56 day donate unit plasma last 7 day . Patients history alcohol drug abuse prior 2 year . Individuals take `` prohibit '' medication relation study ( see point 6 , previous section ) . Individuals history neoplasia . Individuals participate another clinical study either involve medication conclude last 30 day . Individuals previously expose Bifidobacteria specie . Subjects willing maintain glutencontaining diet 3weeks period trial Pregnant woman . Allergies goat milk ; recent plan dietary change , esp . regard gluten intake .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>Coeliac Disease</keyword>
</DOC>